Trials / Terminated
TerminatedNCT02573740
Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment
A Study to Evaluate the Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of Multiple Doses of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment Due to Alzheimer's Disease
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 55 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple dose study of ABT-957 in participants with mild Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) due to AD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-957 | |
| OTHER | Placebo |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2016-06-01
- Completion
- 2016-06-01
- First posted
- 2015-10-12
- Last updated
- 2021-07-06
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02573740. Inclusion in this directory is not an endorsement.